4401 - 4425 of 8654 Results
Title
Year
- Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension2016OPENTitle: Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotensionJournal Name: BMC NeurologyPublisher: Springer Science and Business Media LLCVol: 16Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s12883-016-0665-5Best OA location URL: https://bmcneurol.biomedcentral.com/track/pdf/10.1186/s12883-016-0665-5Citation Count: 4
-
OPENTitle: Clinimetric testing of the comprehensive cervical dystonia rating scaleJournal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 4Start Page: 563End Page: 569Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26534Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/4833533Citation Count: 46
- Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings2016OPENTitle: Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy FindingsJournal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 2Start Page: 250End Page: 256Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26476Citation Count: 77
- Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease2016OPENTitle: Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 7Start Page: 1012End Page: 1019Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26621Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/4931950Citation Count: 34
-
OPENTitle: Clinical and demographic characteristics related to onset site and spread of cervical dystoniaJournal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 12Start Page: 1874End Page: 1882Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26817Best OA location URL: http://doi.org/10.1002/mds.26817Citation Count: 43
-
OPENTitle: Assessing medication role on neuropathological findings in Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 5Start Page: 613End Page: 614Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26536Best OA location URL: http://doi.org/10.1002/mds.26536Citation Count: 0
- Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4)2009OPENTitle: Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4)Journal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 19Issue #: 17Start Page: 4967End Page: 4970Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2009.07.072Best OA location URL: https://doi.org/10.7270/q2tb16zxCitation Count: 36
- Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: A harbinger of freezing of gait?2016OPENTitle: Subliminal gait initiation deficits in rapid eye movement sleep behavior disorder: A harbinger of freezing of gait?Journal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 11Start Page: 1711End Page: 1719Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.26665Best OA location URL: http://doi.org/10.1002/mds.26665Citation Count: 41
-
OPENTitle: Role of Elongation and Secondary Pathways in S6 Amyloid Fibril GrowthJournal Name: Biophysical JournalPublisher: Elsevier BVVol: 102Issue #: 9Start Page: 2167End Page: 2175Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.bpj.2012.03.047Best OA location URL: http://www.cell.com/article/S0006349512003888/pdfCitation Count: 36
- Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators2008OPENTitle: Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGluR4 positive allosteric modulatorsJournal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 18Issue #: 20Start Page: 5626End Page: 5630Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2008.08.087Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3182458Citation Count: 58
- Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: Unexpected ‘molecular switch’ from a closely related mGlu4 positive allosteric modulator2011OPENTitle: Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: Unexpected ‘molecular switch’ from a closely related mGlu4 positive allosteric modulatorJournal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 21Issue #: 23Start Page: 6955End Page: 6959Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2011.09.131Best OA location URL: https://doi.org/10.7270/q2s75grqCitation Count: 18
- Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations2012OPENTitle: Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterationsJournal Name: Neurochemistry InternationalPublisher: Elsevier BVVol: 62Issue #: 2Start Page: 145End Page: 156Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuint.2012.12.001Best OA location URL: http://hdl.handle.net/11336/18335Citation Count: 49
-
OPENTitle: Should We Disclose Amyloid Imaging Results to Cognitively Normal Individuals?Journal Name: Neurodegenerative Disease ManagementPublisher: Informa UK LimitedVol: 3Issue #: 1Start Page: 43End Page: 51Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.2217/nmt.12.75Citation Count: 34
-
OPENTitle: Investigating Convergent Actions of Genes Linked to Familial Parkinson’s DiseaseJournal Name: Neurodegenerative DiseasesPublisher: S. Karger AGVol: 5Issue #: 3-4Start Page: 182End Page: 185Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1159/000113697Best OA location URL: https://www.karger.com/Article/Pdf/113697Citation Count: 43
- PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies2015OPENTitle: PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy BodiesJournal Name: Neurodegenerative DiseasesPublisher: S. Karger AGVol: 16Issue #: 1-2Start Page: 118End Page: 124Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1159/000441421Best OA location URL: http://doi.org/10.1159/000441421Citation Count: 49
-
OPENTitle: LRRK2 and the Stress Response: Interaction with MKKs and JNK-Interacting ProteinsJournal Name: Neurodegenerative DiseasesPublisher: S. Karger AGVol: 7Issue #: 1-3Start Page: 68End Page: 75Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1159/000285509Best OA location URL: https://karger.com/ndd/article-pdf/7/1-3/68/3138541/000285509.pdfCitation Count: 60
- MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials2015OPENTitle: MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trialsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 37Issue #:Start Page: 26End Page: 37Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2015.09.018Best OA location URL: https://www.sciencedirect.com/science/article/am/pii/S0197458015004753Citation Count: 46
- Discovery, Synthesis, and Structure−Activity Relationship Development of a Series of N-(4-Acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu4) with CNS Exposure in Rats2011OPENTitle: Discovery, Synthesis, and Structure−Activity Relationship Development of a Series of N-(4-Acetamido)phenylpicolinamides as Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 (mGlu4) with CNS Exposure in RatsJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 54Issue #: 4Start Page: 1106End Page: 1110Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/jm101271sCitation Count: 48
-
OPENTitle: Sequencing of the GBA coactivator, Saposin C, in Parkinson diseaseJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 72Issue #:Start Page: 187.e1End Page: 187.e3Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2018.06.034Citation Count: 22
- A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology2018OPENTitle: A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathologyJournal Name: Nature NeurosciencePublisher: Springer Science and Business Media LLCVol: 22Issue #: 1Start Page: 47End Page: 56Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41593-018-0298-7Citation Count: 217
- Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease2018OPENTitle: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric diseaseJournal Name: Nature NeurosciencePublisher: Springer Science and Business Media LLCVol: 21Issue #: 10Start Page: 1482End Page: 1492Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41593-018-0223-0Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/6334654Citation Count: 95
- Preparation of biogenic gas vesicle nanostructures for use as contrast agents for ultrasound and MRI2017OPENTitle: Preparation of biogenic gas vesicle nanostructures for use as contrast agents for ultrasound and MRIJournal Name: Nature ProtocolsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 10Start Page: 2050End Page: 2080Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/nprot.2017.081Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/6185898Citation Count: 143
-
OPENTitle: Highlights of the Stockholm Congress: A Clinician's PerspectiveJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 1Issue #: 4Start Page: 277End Page: 279Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12093Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12093Citation Count: 0
-
OPENTitle: Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairmentJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 120Issue #: 6Start Page: 827End Page: 828Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s00401-010-0744-4Best OA location URL: https://europepmc.org/articles/pmc3100801?pdf=renderCitation Count: 84
-
OPENTitle: Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron lossJournal Name: Acta NeuropathologicaPublisher: Springer Science and Business Media LLCVol: 124Issue #: 5Start Page: 665End Page: 680Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1007/s00401-012-1040-2Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/3473167Citation Count: 188